Oncology treatment developer Elekta has received the Food and Drug Administration's 510(k) approval for its PrecisePlan radiotherapy planning system, the company said.
PrecisePlan adds several capabilities to the firm's existing Render-Plan 3-D product, a 2-D and 3-D planning system for radiation therapy. PrecisePlan adds new planning tools and 3-D visualization needed for complex conformal and stereotactic techniques, according to Elekta of Stockholm, Sweden.
For example, PrecisePlan's Fiducial Plan module combines with Elekta Stereotactic Body Frame to provide 3-D spatial referencing, a tool that accurately positions the tumor and thus allows new fractionation patterns with high-dose escalation, the company said.
PrecisePlan networks with Elekta's Precise Treatment Systems to offer comprehensive treatment planning from diagnosis using CT or MRI to confirmation of treatment delivery, according to Elekta.
By AuntMinnie.com staff writers
October 10, 2000
Copyright © 2000 AuntMinnie.com